Citations (56)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (6)
Qiong Wu, Bo Zhang, Yidan Sun, Ran Xu, Xinyi Hu, Shiqi Ren, Qianqian Ma, Chen Chen, Jian Shu, Fuwei Qi, Ting He, Wei Wang & Ziheng Wang. (2019) Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis. OncoTargets and Therapy 12, pages 3545-3563.
Read now
Read now
Yifei Liu, Li Qian, Juanjuan Yang, Hua Huang, Jia Feng, Xiaoli Li, Tingting Bian, Honggang Ke, Jian Liu & Jianguo Zhang. (2018) The expression level and prognostic value of HIPK3 among non-small-cell lung cancer patients in China. OncoTargets and Therapy 11, pages 7459-7469.
Read now
Read now
Hao Zhang, Chen Liang, Xinxin Hou, Ling Wang & Dongsheng Zhang. (2016) Study of the combined treatment of lung cancer using gene-loaded immunomagnetic albumin nanospheres in vitro and in vivo. International Journal of Nanomedicine 11, pages 1039-1050.
Read now
Read now
Chunsheng Li, Ann-Marie Chacko, Jia Hu, Kosei Hasegawa, Jennifer Swails, Luigi Grasso, Wafik S El-Deiry, Nicholas Nicolaides, Vladimir R Muzykantov, Chaitanya R Divgi & George Coukos. (2014) Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model. Cancer Biology & Therapy 15:4, pages 443-451.
Read now
Read now
A Srinivas Reddy & Shuxing Zhang. (2013) Polypharmacology: drug discovery for the future. Expert Review of Clinical Pharmacology 6:1, pages 41-47.
Read now
Read now
Andreas Desiniotis & Natasha Kyprianou. (2011) Advances in the design and synthesis of prazosin derivatives over the last ten years. Expert Opinion on Therapeutic Targets 15:12, pages 1405-1418.
Read now
Read now
Articles from other publishers (50)
Liyan Yu, Xuemei Liang, Jianwei Wang, Guangxiang Ding, Jinhai Tang, Juan Xue, Xin He, Jingxuan Ge, Xianzhang Jin, Zhiyi Yang, Xianwei Li, Hehuan Yao, Hongtao Yin, Wu Liu, Shengchen Yin, Bing Sun & Junxiu Sheng. (2023) Identification of Key Biomarkers and Candidate Molecules in Non-Small-Cell Lung Cancer by Integrated Bioinformatics Analysis. Genetics Research 2023, pages 1-19.
Crossref
Crossref
J.S. Dileep Kumar, Andrei Molotkov, Patrick Carberry, Thomas Chaly, Ramesh Neelamegam & Akiva Mintz. (2022) Radiosynthesis and evaluation of [11C]AG-488, a dual anti-angiogenetic and anti-tubulin PET ligand. Bioorganic & Medicinal Chemistry Letters 74, pages 128941.
Crossref
Crossref
Shruti Choudhary, Arpit Doshi, Lerin Luckett-Chastain, Michael Ihnat, Ernest Hamel, Susan L. Mooberry & Aleem Gangjee. (2021) Potential of substituted quinazolines to interact with multiple targets in the treatment of cancer. Bioorganic & Medicinal Chemistry 35, pages 116061.
Crossref
Crossref
Minglian Qiu, Guoping Li, Pengcheng Wang, Xu Li, Fancai Lai, Ronggang Luo, Bo Liu & Jianbo Lin. (2020) aarF domain containing kinase 5 gene promotes invasion and migration of lung cancer cells through ADCK5-SOX9-PTTG1 pathway. Experimental Cell Research 392:1, pages 112002.
Crossref
Crossref
Vineet Govinda Gupta, Ranga Rao Rangaraju, Rajat Saha & Peush Bajpai. (2018) Pazopanib Monotherapy Is Active in Relapsed and Refractory Metastatic Gastroesophageal Adenocarcinoma and Can Produce Durable Response. Journal of Gastrointestinal Cancer 50:4, pages 943-946.
Crossref
Crossref
Liang Liu, Jianjiao Ni & Xinhong He. (2018) Upregulation of the Long Noncoding RNA SNHG3 Promotes Lung Adenocarcinoma Proliferation. Disease Markers 2018, pages 1-12.
Crossref
Crossref
Sun Zongwen, Kong Song, Zhao Cong, Fu Tian & Zhang Yan. (2017) Evaluation of efficacy and safety for bevacizumab in treating malignant pleural effusions caused by lung cancer through intrapleural injection. Oncotarget 8:69, pages 113318-113330.
Crossref
Crossref
Dinesh Kumar Chellappan, Jestin Chellian, Zhao Yin Ng, Yan Jinn Sim, Chiu Wei Theng, Joyce Ling, Mei Wong, Jia Hui Foo, Goh Jun Yang, Li Yu Hang, Saranyah Nathan, Yogendra Singh & Gaurav Gupta. (2017) The role of pazopanib on tumour angiogenesis and in the management of cancers: A review. Biomedicine & Pharmacotherapy 96, pages 768-781.
Crossref
Crossref
Xia Li, Haiying Wang, Qinggan Ni, Zhiyuan Tang, Jun Ni, Liqin Xu, Hua Huang, Songshi Ni & Jian Feng. (2017) Effects of silencing Rab27a gene on biological characteristics and chemosensitivity of non-small cell lung cancer. Oncotarget 8:55, pages 94481-94492.
Crossref
Crossref
Shuo Wang, Ying-Ying Chen, Yu-Peng Li, Jun Gu, Shu-Dong Gu, Hai Shi, Xue-Song Li, Xiao-Ning Lu, Xiang Li, Shuang-Long Zhang, Kang-Jun Yu, Kun Liu & Li-Li Ji. (2017) DISC1 overexpression promotes non-small cell lung cancer cell proliferation. Oncotarget 8:39, pages 65199-65210.
Crossref
Crossref
Roheeth Kumar Pavana, Shruti Choudhary, Anja Bastian, Michael A. Ihnat, Ruoli Bai, Ernest Hamel & Aleem Gangjee. (2017) Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents. Bioorganic & Medicinal Chemistry 25:2, pages 545-556.
Crossref
Crossref
Susanna Ulahannan. 2017. Cancer Therapeutic Targets. Cancer Therapeutic Targets
537
543
.
Marwa A. Aziz, Rabah A. T. Serya, Deena S. Lasheen, Amal Kamal Abdel-Aziz, Ahmed Esmat, Ahmed M. Mansour, Abdel Nasser B. Singab & Khaled A. M. Abouzid. (2016) Discovery of Potent VEGFR-2 Inhibitors based on Furopyrimidine and Thienopyrimidne Scaffolds as Cancer Targeting Agents. Scientific Reports 6:1.
Crossref
Crossref
Xiaolu Zhai, Liqin Xu, Siya Zhang, Huijun Zhu, Guoxin Mao & Jianfei Huang. (2015) High expression levels of MAGE-A9 are correlated with unfavorable survival in lung adenocarcinoma. Oncotarget 7:4, pages 4871-4881.
Crossref
Crossref
Igor M Bondarenko, Antonella Ingrosso, Paul Bycott, Sinil Kim & Cristina L Cebotaru. (2015) Phase II study of axitinib with doublet chemotherapy in patients with advanced squamous non–small-cell lung cancer. BMC Cancer 15:1.
Crossref
Crossref
Yanyan Jiang, Danny Allen, Veerle Kersemans, Aoife M. Devery, Sivan M. Bokobza, Sean Smart & Anderson J. Ryan. (2015) Acute vascular response to cediranib treatment in human non-small-cell lung cancer xenografts with different tumour stromal architecture. Lung Cancer 90:2, pages 191-198.
Crossref
Crossref
Fadi Najjar, Ghassan Al-Massarani, Israa Banat & Moosheer Alammar. (2015) Circulating Endothelial Cells for Evaluation of Tumor Response in Non-Small Cell lung cancer patients receiving first-line chemotherapy. The International Journal of Biological Markers 30:4, pages 374-381.
Crossref
Crossref
Gennaro Gadaleta-Caldarola, Stefania Infusino, Rosa Divella, Emanuela Ferraro, Antonio Mazzocca, Ferruccio De Rose, Gianfranco Filippelli, Ines Abbate & Mario Brandi. (2015) Sorafenib: 10 years after the first pivotal trial. Future Oncology 11:13, pages 1863-1880.
Crossref
Crossref
Tian-Yan Luan, Tie-Nian Zhu, Yu-Jie Cui, Gang Zhang, Xue-Jing Song, Dong-Mei Gao, Yi-Mei Zhang, Qing-Lan Zhao, Shuang Liu, Tong-Yi Su & Rui-Jing Zhao. (2015) Expression of caveolin-1 is correlated with lung adenocarcinoma proliferation, migration, and invasion. Medical Oncology 32:7.
Crossref
Crossref
Tong FuWei QuFan QiuYan LiGuoqiang ShaoWei TianZichun HuaYingjian ZhangFeng Wang. (2014)
99m
Tc-3P-RGD
2
Micro-Single-Photon Emission Computed Tomography/Computed Tomography Provides a Rational Basis for Integrin α
v
β
3
-Targeted Therapy
. Cancer Biotherapy and Radiopharmaceuticals 29:9, pages 351-358.
Crossref
Crossref
Fadi Najjar, Moosheer Alammar, Marroan Bachour & Ghassan Al-Massarani. (2014) Circulating Endothelial Cells as a Biomarker in Non-Small Cell Lung Cancer Patients: Correlation with Clinical Outcome. The International Journal of Biological Markers 29:4, pages 337-344.
Crossref
Crossref
Kelong Han, Jin Jin, Mauricio Maia, John Lowe, Martina A. Sersch & David E. Allison. (2014) Lower Exposure and Faster Clearance of Bevacizumab in Gastric Cancer and the Impact of Patient Variables: Analysis of Individual Data from AVAGAST Phase III Trial. The AAPS Journal 16:5, pages 1056-1063.
Crossref
Crossref
Qiong He, Jing Gao, Sai Ge, Tingting Wang, Yanyan Li, Zhi Peng, Yilin Li & Lin Shen. (2014) Axitinib alone or in combination with chemotherapeutic drugs exerts potent antitumor activity against human gastric cancer cells in vitro and in vivo. Journal of Cancer Research and Clinical Oncology 140:9, pages 1575-1583.
Crossref
Crossref
Chunsheng Li, Junying Wang, Jia Hu, Yi Feng, Kosei Hasegawa, Xiaohui Peng, Xingmei Duan, Aizhi Zhao, John L. Mikitsh, Vladimir R. Muzykantov, Ann-Marie Chacko, Daniel A. Pryma, Steven M. Dunn & George Coukos. (2014) Development, optimization, and validation of novel anti-TEM1/CD248 affinity agent for optical imaging in cancer. Oncotarget 5:16, pages 6994-7012.
Crossref
Crossref
Qiong Wang, Shaoqing Shi, Weiyang He, Mabel T. Padilla, Lin Zhang, Xia Wang, Bin Zhang & Yong Lin. (2014) Retaining MKP1 expression and attenuating JNK-mediated apoptosis by RIP1 for cisplatin resistance through miR-940 inhibition. Oncotarget 5:5, pages 1304-1314.
Crossref
Crossref
Rebecca S. Heist, Xiaofei Wang, Lydia Hodgson, Gregory A. Otterson, Thomas E. Stinchcombe, Leena Gandhi, Miguel A. Villalona-Calero, Peter Watson, Everett E. Vokes & Mark A. Socinski. (2014) CALGB 30704 (Alliance): A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non–Small-Cell Lung Cancer. Journal of Thoracic Oncology 9:2, pages 214-221.
Crossref
Crossref
Qiong Wang, Wenshu Chen, Lang Bai, Wenjie Chen, Mabel T. Padilla, Amy S. Lin, Shaoqing Shi, Xia Wang & Yong Lin. (2014) Receptor-interacting Protein 1 Increases Chemoresistance by Maintaining Inhibitor of Apoptosis Protein Levels and Reducing Reactive Oxygen Species through a microRNA-146a-mediated Catalase Pathway. Journal of Biological Chemistry 289:9, pages 5654-5663.
Crossref
Crossref
Hiroyuki Suzuki, Mitsuro Fukuhara, Takumi Yamaura, Satoshi Mutoh, Naoyuki Okabe, Hiroshi Yaginuma, Takeo Hasegawa, Atsushi Yonechi, Jun Osugi, Mika Hoshino, Takashi Kimura, Mitsunori Higuchi, Yutaka Shio, Kazuya Ise, Kazuyoshi Takeda & Mitsukazu Gotoh. (2013) Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer. Journal of Translational Medicine 11:1.
Crossref
Crossref
Qinying Sun, Xiaopeng Yao, Yunye Ning, Wei Zhang, Guowu Zhou & Yuchao Dong. (2013) Overexpression of response gene to complement 32 (RGC32) promotes cell invasion and induces epithelial?mesenchymal transition in lung cancer cells via the NF-?B signaling pathway. Tumor Biology 34:5, pages 2995-3002.
Crossref
Crossref
Andreas Pircher, Michael Fiegl, Gerold Untergasser, Isabel Heidegger, Michael Medinger, Johann Kern & Wolfgang Hilbe. (2013) Favorable prognosis of operable non-small cell lung cancer (NSCLC) patients harboring an increased expression of tumor endothelial markers (TEMs). Lung Cancer 81:2, pages 252-258.
Crossref
Crossref
Jeffrey R. Infante, Silvia Novello, Wen Wee Ma, Grace K. Dy, Johanna C. Bendell, Anne Huff, Qiong Wang, A. Benjamin Suttle, Robert Allen, Chun-Fang Xu, Lone H. Ottesen, Howard A. BurrisIIIIII & Alex A. Adjei. (2012) Phase Ib trial of the oral angiogenesis inhibitor pazopanib administered concurrently with pemetrexed in patients with advanced solid tumors. Investigational New Drugs 31:4, pages 927-936.
Crossref
Crossref
Corey J. Langer, Tony Mok & Pieter E. Postmus. (2013) Targeted agents in the third-/fourth-line treatment of patients with advanced (stage III/IV) non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 39:3, pages 252-260.
Crossref
Crossref
Liqin Xu, Yan Qin, Jianfei Huang, Jing Qin, Jun Gu, Huijun Zhu, Hong Liu, Yifeng Cai, Xinhua Wu & Jian Feng. (2013) Effect of rapamycin-induced tumor vessel thrombosis combined with docetaxel in non-small-cell lung cancer. Anti-Cancer Drugs 24:4, pages 406-414.
Crossref
Crossref
Jing Li, Manish Gupta, Denise Jin, Yan Xin, Jennifer Visich & David E. Allison. (2012) Characterization of the long-term pharmacokinetics of bevacizumab following last dose in patients with resected stage II and III carcinoma of the colon. Cancer Chemotherapy and Pharmacology 71:3, pages 575-580.
Crossref
Crossref
Yong-Ying Xiao, Ping Zhan, Dong-Mei Yuan, Hong-Bing Liu, Tang-Feng Lv, Yong Song & Yi Shi. (2012) Chemotherapy plus multitargeted antiangiogenic tyrosine kinase inhibitors or chemotherapy alone in advanced NSCLC: a meta-analysis of randomized controlled trials. European Journal of Clinical Pharmacology 69:2, pages 151-159.
Crossref
Crossref
Daniel Spira, Helge Neumeister, Sven Michael Spira, J?rgen Hetzel, Werner Spengler, Claus Hann von Weyhern & Marius Horger. (2013) Assessment of Tumor Vascularity in Lung Cancer Using Volume Perfusion CT (VPCT) With Histopathologic Comparison. Journal of Computer Assisted Tomography 37:1, pages 15-21.
Crossref
Crossref
Yong-Ying Xiao, Ping Zhan, Dong-Mei Yuan, Hong-Bing Liu, Tang-Feng Lv, Yi Shi & Yong Song. (2013) Chemotherapy plus Vandetanib or Chemotherapy Alone in Advanced Non-small Cell Lung Cancer: A Meta-analysis of Four Randomised Controlled Trials. Clinical Oncology 25:1, pages e7-e15.
Crossref
Crossref
Ruth Plummer, Ayman Madi, Melinda Jeffels, Heike Richly, Bahar Nokay, Stephen Rubin, Howard A. Ball, Steve Weller, Jeffrey Botbyl, Diana M. Gibson & Max E. Scheulen. (2012) A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 71:1, pages 93-101.
Crossref
Crossref
Susanna Ulahannan. 2016. Cancer Therapeutic Targets. Cancer Therapeutic Targets
1
7
.
Edward B. Garon, Dachuang Cao, Ekaterine Alexandris, William J. John, Sergey Yurasov & Maurice Perol. (2012) A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design. Clinical Lung Cancer 13:6, pages 505-509.
Crossref
Crossref
Luis G. Paz-AresBonne BiesmaDavid HeigenerJoachim von PawelTimothy EisenJaafar BennounaLi ZhangMeilin LiaoYan SunSteven GansKostas SyrigosEtienne Le MarieMaya GottfriedJohan VansteenkisteVincente AlberolaUwe Phillip StraussElaine MontegriffoTeng Jin OngArmando Santoro. (2012) Phase III, Randomized, Double-Blind, Placebo-Controlled Trial of Gemcitabine/Cisplatin Alone or With Sorafenib for the First-Line Treatment of Advanced, Nonsquamous Non–Small-Cell Lung Cancer. Journal of Clinical Oncology 30:25, pages 3084-3092.
Crossref
Crossref
Lawson Eng, Abul Kalam Azad, Steven Habbous, Vincent Pang, Wei Xu, Anke H. Maitland-van der Zee, Sevtap Savas, Helen J. Mackay, Eitan Amir & Geoffrey Liu. (2012) Vascular Endothelial Growth Factor Pathway Polymorphisms as Prognostic and Pharmacogenetic Factors in Cancer: A Systematic Review and Meta-analysis. Clinical Cancer Research 18:17, pages 4526-4537.
Crossref
Crossref
Jian Feng, Xuesong Zhang, Huijun Zhu, Xudong Wang, Songshi Ni & Jianfei Huang. (2012) High Expression of FoxP1 Is Associated With Improved Survival in Patients With Non–Small Cell Lung Cancer. American Journal of Clinical Pathology 138:2, pages 230-235.
Crossref
Crossref
Jian Feng, Xuesong Zhang, Huijun Zhu, Xudong Wang, Songshi Ni & Jianfei Huang. (2012) FoxQ1 Overexpression Influences Poor Prognosis in Non-Small Cell Lung Cancer, Associates with the Phenomenon of EMT. PLoS ONE 7:6, pages e39937.
Crossref
Crossref
MAKITO MIYAKE, SATOSHI ANAI, KIYOHIDE FUJIMOTO, SAYURI OHNISHI, MASAOMI KUWADA, YASUSHI NAKAI, TAKESHI INOUE, ATSUSHI TOMIOKA, NOBUMICHI TANAKA & YOSHIHIKO HIRAO. (2012) 5-fluorouracil enhances the antitumor effect of sorafenib and sunitinib in a xenograft model of human renal cell carcinoma. Oncology Letters 3:6, pages 1195-1202.
Crossref
Crossref
Wei Huang, Bo Deng, Ru-Wen Wang, Qun-You Tan, Yong He, Yao-Guang Jiang & Jing-Hai Zhou. (2012) BCAR1 Protein Plays Important Roles in Carcinogenesis and Predicts Poor Prognosis in Non-Small-Cell Lung Cancer. PLoS ONE 7:4, pages e36124.
Crossref
Crossref
R J Young, A W Tin, N J Brown, M Jitlal, S M Lee & P J Woll. (2012) Analysis of circulating angiogenic biomarkers from patients in two phase III trials in lung cancer of chemotherapy alone or chemotherapy and thalidomide. British Journal of Cancer 106:6, pages 1153-1159.
Crossref
Crossref
Wei Zhou, Li Wang, Shan-miao Gou, Tong-ling Wang, Meng Zhang, Tao Liu & Chun-you Wang. (2012) ShRNA silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic cancer. Cancer Letters 316:2, pages 178-186.
Crossref
Crossref
Roberta E Burden, Jill Caswell, Francois Fay & Christopher J Scott. (2012) Recent advances in the application of antibodies as therapeutics. Future Medicinal Chemistry 4:1, pages 73-86.
Crossref
Crossref
G Bousquet, J Alexandre, C Le Tourneau, F Goldwasser, S Faivre, H de Mont-Serrat, R Kaiser, J L Misset & E Raymond. (2011) Phase I study of BIBF 1120 with docetaxel and prednisone in metastatic chemo-naive hormone-refractory prostate cancer patients. British Journal of Cancer 105:11, pages 1640-1645.
Crossref
Crossref